Should sunitinib still be used in the treatment of metstatic kidney cancer?

(3:9)

Sunitinib Therapy at Progression of Metastatic GIST

(3:46)

Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

(1:23)

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

(1:1econd)

Sunitinib with or without surgery for metastatic renal cell carcinoma

(4:6)

Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy

(55)

Sunitinib for treating high-risk RCC

(1:56)

Dr. George on the Use of Adjuvant Sunitinib in RCC

(1:35)

Sunitinib 4/2 vs 2/1 Schedule for Patients with mRCC

(7:4)

Dosing Schedule of Sunitinib in Renal Cell Carcinoma

(6:57)

NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

(2:34)

Dosing Sunitinib and Pazopanib in Renal Cell Carcinoma

(7:14)

Who is Your Ideal Sunitinib Patient? Camillo Porta, M.D.

(13:25)

Older patients benefit from lower doses of sunitinib in renal cell carcinoma

(5:10)

Adjuvant Sunitinib’s Role in the Treatment of RCC

(5:54)

Examining Kidney Toxicities of Sunitinib and Imatinib in Long Term GIST Therapy

(53:)

INTRIGUE: ripretinib vs. sunitinib in patients with advanced GISTs

(2:26)

Dr. Figlin on Sunitinib for Patients With RCC

(1:24)

STAR: First-line sunitinib or pazopanib in the treatment of locally advanced and/or metastatic r...

(15:21)

Adjuvant Sunitinib for High Risk Renal Cell Carcinoma: Not Ready for Prime Time

(19:55)